MIRA Pharmaceuticals Reports Preclinical MIRA-55 Pain Relief Results
The company said oral MIRA-55 reduced chronic inflammatory pain in a 21-day preclinical study, with effects comparable to celecoxib.
Story updates
12:05:03 PM UTC
SquawkNews
MIRA Pharmaceuticals reported a 21-day preclinical study where oral MIRA-55 reduced pain hypersensitivity with effects comparable to celecoxib at higher doses, sustained without observed tolerance, and reduced swelling. The company plans an IND submission in Q1 2027, subject to completion of activi…